Literature DB >> 20007270

Heterotypic humoral and cellular immune responses following Norwalk virus infection.

Lisa C Lindesmith1, Eric Donaldson, Juan Leon, Christine L Moe, Jeffrey A Frelinger, Robert E Johnston, David J Weber, Ralph S Baric.   

Abstract

Norovirus immunity is poorly understood as the limited data available on protection after infection are often contradictory. In contrast to the more prominent GII noroviruses, GI norovirus infections are less frequent in outbreaks. The GI noroviruses display very complex patterns of heterotypic immune responses following infection, and many individuals are highly susceptible to reinfection. To study the immune responses and mechanisms of GI.1 persistence, we built structural models and recombinant virus-like particles (VLPs) of five GI strains: GI.1-1968, GI.1-2001, GI.2-1999, GI.3-1999, and GI.4-2000. Structural models of four GI genotype capsid P domain dimers suggested that intragenotype structural variation is limited, that the GI binding pocket is mostly preserved between genotypes, and that a conserved, surface-exposed epitope may allow for highly cross-reactive immune responses. GI VLPs bound to histo-blood group antigens (HBGAs) including fucose, Lewis, and A antigens. Volunteers infected with GI.1-1968 (n = 10) had significant increases between prechallenge and convalescent reactive IgG for all five GI VLPs measured by enzyme immunoassay. Potential cross-neutralization of GI VLPs was demonstrated by convalescent-phase serum cross-blockade of GI VLP-HBGA interaction. Although group responses were significant for all GI VLPs, each individual volunteer demonstrated a unique VLP blockade pattern. Further, peripheral blood mononuclear cells (PBMCs) were stimulated with each of the VLPs, and secretion of gamma interferon (IFN-gamma) was measured. As seen with blockade responses, IFN-gamma secretion responses differed by individual. Sixty percent responded to at least one GI VLP, with only two volunteers responding to GI.1 VLP. Importantly, four of five individuals with sufficient PBMCs for cross-reactivity studies responded more robustly to other GI VLPs. These data suggest that preexposure history and deceptive imprinting may complicate PBMC and B-cell immune responses in some GI.1-1968-challenged individuals and highlight a potential complication in the design of efficacious norovirus vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007270      PMCID: PMC2812379          DOI: 10.1128/JVI.02179-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  92 in total

1.  Emergence of a new norovirus variant in Scotland in 2006.

Authors:  W E Adamson; R N Gunson; A Maclean; W F Carman
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

2.  Genetic variation of the norovirus GII-4 genotype associated with a large number of outbreaks in Chiba prefecture, Japan.

Authors:  M Okada; T Ogawa; H Yoshizumi; H Kubonoya; K Shinozaki
Journal:  Arch Virol       Date:  2007-09-14       Impact factor: 2.574

3.  Structural basis for the receptor binding specificity of Norwalk virus.

Authors:  Weiming Bu; Aygun Mamedova; Ming Tan; Ming Xia; Xi Jiang; Rashmi S Hegde
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

4.  Cross-reactive memory CD8(+) T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner.

Authors:  Coreen M Beaumier; Anuja Mathew; Hema S Bashyam; Alan L Rothman
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

5.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.

Authors:  Jens Wrammert; Kenneth Smith; Joe Miller; William A Langley; Kenneth Kokko; Christian Larsen; Nai-Ying Zheng; Israel Mays; Lori Garman; Christina Helms; Judith James; Gillian M Air; J Donald Capra; Rafi Ahmed; Patrick C Wilson
Journal:  Nature       Date:  2008-04-30       Impact factor: 49.962

6.  Gastroenteritis outbreak caused by waterborne norovirus at a New Zealand ski resort.

Authors:  Joanne Hewitt; Derek Bell; Greg C Simmons; Malet Rivera-Aban; Sandro Wolf; Gail E Greening
Journal:  Appl Environ Microbiol       Date:  2007-10-26       Impact factor: 4.792

7.  Epidemics of gastroenteritis during 2006 were associated with the spread of norovirus GII.4 variants 2006a and 2006b.

Authors:  Elise T-V Tu; Rowena A Bull; Gail E Greening; Joanne Hewitt; Michael J Lyon; John A Marshall; Christopher J McIver; William D Rawlinson; Peter A White
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

8.  Evaluation of removal of noroviruses during wastewater treatment, using real-time reverse transcription-PCR: different behaviors of genogroups I and II.

Authors:  Allegra Kyria da Silva; Jean-Claude Le Saux; Sylvain Parnaudeau; Monique Pommepuy; Menachem Elimelech; Françoise S Le Guyader
Journal:  Appl Environ Microbiol       Date:  2007-10-12       Impact factor: 4.792

9.  Mechanisms of GII.4 norovirus persistence in human populations.

Authors:  Lisa C Lindesmith; Eric F Donaldson; Anna D Lobue; Jennifer L Cannon; Du-Ping Zheng; Jan Vinje; Ralph S Baric
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

10.  Tentative T cells: memory cells are quick to respond, but slow to divide.

Authors:  Jason K Whitmire; Boreth Eam; J Lindsay Whitton
Journal:  PLoS Pathog       Date:  2008-04-11       Impact factor: 6.823

View more
  66 in total

1.  Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010.

Authors:  Sayaka Takanashi; Qiuhong Wang; Ning Chen; Quan Shen; Kwonil Jung; Zhenwen Zhang; Masaru Yokoyama; Lisa C Lindesmith; Ralph S Baric; Linda J Saif
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

2.  Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects.

Authors:  Jesica Swanstrom; Lisa C Lindesmith; Eric F Donaldson; Boyd Yount; Ralph S Baric
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

3.  Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.

Authors:  Maria Malm; Kirsi Tamminen; Suvi Lappalainen; Hanni Uusi-Kerttula; Timo Vesikari; Vesna Blazevic
Journal:  Clin Vaccine Immunol       Date:  2015-04-22

4.  Human norovirus infection and the acute serum cytokine response.

Authors:  K L Newman; C L Moe; A E Kirby; W D Flanders; C A Parkos; J S Leon
Journal:  Clin Exp Immunol       Date:  2015-09-22       Impact factor: 4.330

Review 5.  Norovirus.

Authors:  Elizabeth Robilotti; Stan Deresinski; Benjamin A Pinsky
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

6.  Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication.

Authors:  Larissa B Thackray; Erning Duan; Helen M Lazear; Amal Kambal; Robert D Schreiber; Michael S Diamond; Herbert W Virgin
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

7.  Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus.

Authors:  Nadim J Ajami; Meagan A Barry; Berenice Carrillo; Zana Muhaxhiri; Frederick H Neill; B V Venkataram Prasad; Antone R Opekun; Mark A Gilger; David Y Graham; Robert L Atmar; Mary K Estes
Journal:  Clin Vaccine Immunol       Date:  2012-10-03

8.  Identification and characterization of antibody-binding epitopes on the norovirus GII.3 capsid.

Authors:  Jackie E Mahar; Nicole C Donker; Karin Bok; Gert H Talbo; Kim Y Green; Carl D Kirkwood
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

9.  Norovirus vaccine development: next steps.

Authors:  Robert L Atmar; Mary K Estes
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

Review 10.  Norovirus immunology: Of mice and mechanisms.

Authors:  Kira L Newman; Juan S Leon
Journal:  Eur J Immunol       Date:  2015-08-25       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.